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Specific chromosomal abnormalities are increasingly recognised to be associated with particular tumour subtypes. These cytogenetic
abnormalities define the sites of specific genes, the alteration of which is implicated in the neoplastic process. We used comparative
genomic hybridisation (CGH) to examine DNA from different breast and ovarian cancer cell lines for variations in DNA sequence
copy number compared with the same normal control. We also compared different sources of the MCF7 breast line by both CGH
and cDNA expression arrays. Some of the differences between the subcultures were extensive and involved large regions of the
chromosome. Differences between the four subcultures were observed for gains of 2q, 5p, 5q, 6q, 7p, 7q, 9q, 10p, 11q, 13q, 14q,
16q, 18p and 20p, and losses of 4q, 5p, 5q, 6q, 7q, 8p, 11p, 11q, 12q, 13q, 15q, 19p, 19q, 20p, 21q, 22q and Xp. However, few
variations were found between two subcultures examined, 5 months apart, from the same initial source. The RNA arrays also
demonstrated considerable variation between the three different subcultures, with only 43% of genes expressed at the same levels in
all three. Moreover, the patterns of the expressed genes did not always reflect our observed CGH aberrations. These results
demonstrate extensive genomic instability and variation in RNA expression during subculture and provide supportive data for
evidence that cell lines do evolve in culture, thereby weakening the direct relevance of such cultures as models of human cancer. This
work also reinforces the concern that comparisons of published analyses of cultures of the same name may be dangerous.
British Journal of Cancer (2004) 90, 476–482. doi:10.1038/sj.bjc.6601405 www.bjcancer.com
& 2004 Cancer Research UK
Keywords: CGH; expression arrays; cell culture; breast cancer; ovarian cancer
                                                 
Long-term culture in vitro has represented the most commonly
used experimental model of cancer for the past 40 years (Goldin
et al, 1979, pp. 165–245; Boyd, 1989, pp. 1–12; Monks et al, 1991).
Even though the focus of the NCI screen has changed in recent
years to become more tissue specific and molecularly targeted,
heavy reliance is still placed on well-characterised long-term cell
culture lines. This is of concern since phenotypic diversity has
been demonstrated between established cell lines and the primary
tumour from which they were cultured (Band et al, 1990; Lukashov
and Goudsmit, 1995; Sen et al, 1995). Moreover, differences in
biological properties have been demonstrated between sublines of
both haematopoietic and breast cell lines (Osborne et al, 1987;
Band et al, 1990; Crepin et al, 1990; Lukashov and Goudsmit,
1995). However, long-term subcultures have not been examined
for variation in expression profiling and genomic (chromosomal)
abnormalities.
In this study, we report considerable variation between different
cultures of the MCF7 cell line and lesser variation between
different cultures of three ovarian cell lines. The extent of
differences was more pronounced for a particular cell line
interlaboratory than within the same laboratory at different time
points. These results provide supportive data for evidence that cell
lines do evolve in culture, thereby weakening the direct relevance
of such cultures as models of human cancer. This work also
reinforces the concern that comparisons of published analyses of
cultures of the same name may be dangerous.
In order to identify new drug resistance genes, we have applied
the technique of comparative genomic hybridisation (CGH)
(Kallioniemi et al, 1992) to screen for chromosomal abnormalities
specific to the acquisition of resistance in long-term culture cell
lines (Leyland-Jones et al, 1999). We have demonstrated the
validity of this approach by identifying high-level amplifications of
genes known to be associated with specific resistance mechanisms
(Hiorns et al, 1999). CGH ratios were determined for a series of
breast and ovarian carcinoma cell lines. We noted considerable
variation in the CGH patterns between two cultures of the same
cell line obtained from different laboratories. This observation
prompted us to investigate further cell lines. For four of the cell
lines (one breast and three ovarian), we made a comparison of
different sources of the tumour cell line (against the same normal
control). For one breast (MCF7) and one ovarian (CH1) cell line,
we made a comparison of the aberrations present in cultures from
the same laboratory 5 months apart. For one cell line (MCF7), we
obtained cultures that had been independently maintained in
different geographical locations over a number of generations. In
order to compare the expression levels of certain genes with their
genomic representation, we used cDNA arrays (Botwell, 1999) to
examine different patterns of RNA expression between these
different cultures.
Among the methods available for comprehensive analysis of
RNA expression, cDNA microarrays were chosen for their ability
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sto detect static information on specific gene expression and
dynamic information on the levels of gene expression in a single
experiment. From the commercially available microarrays, we
chose the Atlast cancer arrays (Clontech, Palo Alto, USA) since
the cDNAs on the filters are known genes preselected for their
involvement in cancer and grouped according to their involvement
in specific processes. The sensitivity of this filter-based,
32P-probe-
labelled methodology is known to be limited to high and medium
abundance genes.
MATERIALS AND METHODS
Cell lines
These cell lines were deliberately chosen to represent realistic
diversity in the scientific community. In particular, for the MCF7,
the McGill lines came from an NIH source; the two differently
timed aliquots were carefully controlled in the senior author’s
laboratory. The Nottingham and ICR cell lines were both obtained
from ATCC and were obviously grown in different laboratories,
but under conditions suitable for collaboration.
A series of cell lines previously established from breast and
ovarian carcinomas were passaged independently for a number of
years in long-term culture. Cell lines MCF7(b), A2780(a), 41M(a)
and CH1(a) were obtained from the laboratory of LRK; cell lines
OVCAR-3, A2780(b), 41M(b) and CH1(b and c) from the
laboratory of LAS; cell lines MCF7 (c and d) from the laboratory
of BL-J; and cell line MCF7(a) from the laboratory of TDB. Two
aliquots of the MCF7 cell line (c and d) and two of the CH1 cell line
(b and c) were sampled 5 months apart, having been kept in
continuous passage during the intervening period.
41M and A2780 are ovarian carcinoma cell lines established
from previously untreated patients. OVCAR-3 was established
from the malignant ascites of a patient with progressive ovarian
adenocarcinoma. CH1 was established from an ovarian carcinoma
patient previously treated with, and resistant to, cisplatin and
carboplatin. MCF7 is a breast cancer cell line established from a
previously untreated patient. All cell lines were aneuploid. All cell
lines were maintained as monolayers in Dulbecco’s minimum
essential medium supplemented with 10% foetal calf serum,
50mgml
1 gentamicin, 0.5mgml
1 hydrocortisone and 2mML -
glutamine, in a 5% CO2 atmosphere. For the RNA expression
studies, all three MCF7 cell lines were plated at the same densities,
appeared to grow at equal rates and were sampled at the same time
points.
CGH
DNA was extracted from harvested cells by the conventional
phenol/chloroform technique. DNA (1mg) from each cell line was
labelled for 20h with Biotin-High-Prime (Boehringer Mannheim,
Lewes, UK) using their supplied protocol. ‘Normal’ control DNA
(1mg) was labelled with Digoxigenin-High-Prime (Boehringer).
Unincorporated nucleotides were removed using Nick columns
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Figure 1 Idiogram of the human karyotype showing regions of amplification (green) and deletion (red) in DNA from the MCF7 cell line from different
sources: (a) University of Nottingham; (b) Institute of Cancer Research (Sutton); (c) McGill University (Montreal) April 1996; and (d) McGill University
(Montreal) August 1996.
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s(Pharmacia, St Albans, UK). Equal amounts (1mg) of each DNA
were combined together with a 50-fold excess of COT1 DNA
(Gibco/BRL, Paisley, UK), ethanol precipitated and resuspended in
10ml Hybrisol VIII (Oncor, Gaithersburg, MD, USA). This probe
mixture was then denatured at 751C for 8min, chilled on ice and
warmed to 371C, followed by hybridisation to slides containing
‘normal male’ lymphocyte metaphases (Vysis, Downers Grove, IL,
USA). Hybridisation and washing conditions were described
previously as (Hiorns, in press).
Slides were examined using an Axioskop microscope (Carl Zeiss,
Welwyn Garden City, UK) equipped with appropriate filters.
Images were collected using a CCD camera (Photometrics, Tucson,
AZ, USA) and Quipst software (Vysis). In order to control against
small changes in hybridisation efficiency, at least 10 metaphases
were captured for each hybridisation; the chromosomes were
karyotyped and the axis defined based on the DAPI banding
pattern. The DAPI image as used as a mask for the red and green
images to exclude background fluorescence. The total image
intensity for the masked red and green images was then
independently normalised to accommodate differences in the
image capture, so that the average red:green ratio for each cell was
1.0. The red:green ratios for cross-sections of each chromosome
were measured perpendicular to the axis. The ratio profiles of 10
metaphases were averaged and represented graphically. Chromo-
somal imbalances affecting more than 30% of the cell population
were identified when the ratio was greater than 1.15–1.20 for gains
and less than 0.85–0.80 for losses (all imbalances were within 99%
confidence limits). The heterochromatic regions consisting of
clustered repetitive sequences were excluded from the analysis as
were the telomeres of all chromosomes.
Expression arrays
Total RNA was extracted from cell lines in exponential growth
phase, using the Atlast Pure RNA Isolation Kit (Clontech, Palo
Alto, USA) including all optional purification steps. A measure of
1mg of each RNA was reverse-transcribed using gene-specific
primers and Moloney murine leukaemia virus in the presence of
[a-
32P]dATP. The cDNA probes were purified from unincorpo-
rated nucleotides using Chroma Spin-200 columns (Clontech, Palo
Alto, USA) and hybridised overnight at 681C to Atlast cancer
arrays (Clontech, version 1 which analyses 588 human cDNA’s,
nine housekeeping cDNA’s and negative controls). A series of
high-stringency washes were performed, using the protocol
supplied. The hybridisation pattern was detected using a
phosphorimager. Signals greater than twice the background were
considered positive. The ratio of signal intensity for the expressed
genes was compared to that of the housekeeping genes using
AtlasImaget software (Clonetech). Comparisons between the cell
lines were carried out on a paired basis using the same software.
Differences between expression levels were considered significant
according to the accepted criteria of (i) a ratio difference of more
than two-fold, or (ii) an intensity difference of more than the two
backgrounds combined.
RESULTS
Breast cancer cell line CGH results: overall agreement with
literature
The genomic imbalances identified in the MCF7 cell line are in
broad agreement with the frequently observed changes in the
literature, including both those reported for primary human breast
carcinomas (Nishizaki et al, 1997; Tirkkonen et al, 1998) and cell
lines (Kallioniemi et al, 1994; Jones et al, 2000). The most
frequently observed changes in our four different MCF7 sub-
cultures included consistent gains of 1q, 3p, 3q, 8q, 12q, 15q, 17q
and 20q together with persistent losses of 9p, 17p, 18q and X. In
particular, we observed the gains 3p14 and 14q reported by
Table 1 Amplifications (green) and deletions (red) of genomic sequences identified in ovarian tumours and the ovarian tumour-derived cell
lines: Ovcar, A2780, 41M and CH1
Cell line
Chromosome
123456789 1 0 1 1 1 2 1 3 1 4 1 5 1 6 1 7 1 8 1 9 2 0 2 1 2 2 x
A2780(a and b)
41M(a)
41M(b)
CH1(a)
CH1(b)
CH1(c)
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However, the gain of 14q was only observed in the cell lines from
one of our three laboratories (subcultures c and d).
Striking differences between four MCF7 subcultures
We note surprising variation in the chromosomal aberration
patterns between the four different MCF7 subcultures (illustrated
in Figure 1). The following differences between the four
subcultures were observed: gains of 2q, 5p, 5q, 6q, 7p, 7q, 9q,
10p, 11q, 13q, 14q, 16q, 18p and 20p; and losses of 4q, 5p, 5q, 6q,
7q, 8p, 11p, 11q, 12q, 13q, 15q, 19p, 19q, 20p, 21q, 22q and X. Some
of the differences between the subcultures were extensive involving
large regions of the chromosome. Many of the changes between
our cell lines are similar to those observed by Jones et al (2000). It
is reassuring to note fewer variations between the two subcultures
from the same laboratory (c and d) which were examined over a
period of 5 months in continuous passage. In all, 15 differences
were noted between subcultures (c) and (d) in contrast to 22
differences between (a) and (b), 30 differences between (a) and (c),
and 34 differences between (b) and (c).
Fewer CGH differences between ovarian cell line
subcultures
The genomic aberrations identified by CGH in the ovarian cell
lines studied (A2780, CH1 and 41M) are listed in Table 1. The
ovarian cancer cell lines showed a wide variation in the number
and location of genomic imbalances. In contrast to the MCF7
breast line, each ovarian cancer cell line showed a much smaller
degree of variation both between different laboratories and with
time.
Similarities between MCF7 subculture expression patterns
Similar patterns of RNA expression were observed for all three of
the MCF7 subcultures (a, b and d) both with respect to specific
genes and the levels of gene expression (see Figure 2). In all, 116
genes were expressed at levels greater than 0.01% in one or more of
the cultures; this number is similar to that reported by Sehgal et al
(1998) in GMTT glioblastoma cells but less than that reported by
Xie et al (1998) in HL-60 leukaemia cells. A total of 52 genes
showed the same relative levels of expression in all three cultures.
Sixty-four genes demonstrated variability in levels of
expression between the different subcultures
The chromosomal location and relative expression levels for these
genes are listed in Table 2. All 64 genes either showed a ratio
difference greater than two-fold or an intensity difference between
two subcultures greater than the two background intensities
MCF7(a)
MCF7(b)
MCF7(d)
Figure 2 Clonetech ‘Cancer Array’ filters hybridised with cDNA from
MCF7 sublines from different sources: (a) University of Nottingham; (b)
Institute of Cancer Research (Sutton); and (d) McGill University (Montreal).
Each hybridisation was to a new replicate filter; (none were reprobed).
MCF7(a)
MCF7(b)
MCF7(d)
36 1 2
36 1 2
36 1 2
Figure 3 CGH ratio profiles and accompanying idiograms for selected
chromosomes for the three MCF7 cell lines: (a) University of Nottingham;
(b) Institute of Cancer Research (Sutton); and (d) McGill University
(Montreal). The ratio profiles are shown together with the threshold lines
for amplification in green on the right and deletion in red on the left. The
areas which exceed the threshold are also illustrated in green or red
alongside the idiogram. The heterochromatic regions (which are excluded
from the analysis) are shown hatched on the idiogram.
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fold).
Differences in gene expression (for example, ZRP-1, fau,
RAD23A) between some of the subcultures were profound.
Moreover, large differences were observed in expression levels of
key genes involved in multiple cellular processes – signal
transduction, cytoskeletal maintenance, transport, adhesion, on-
cogenesis, apoptosis, etc.
Table 2 Comparative expression levels of the 45% of genes differentially expressed between at least two of the cell lines
Chromosome location Gene name MCF7 (a)
a MCF7 (b)
a MCF7 (d)
a
1p13.21 rhoC 3.87 6.48 3.69
1p13.3 Glutathione-S-transferase (GST) 7.40 3.57 3.47
2p10–12 rhoB 15.29 10.63 3.61
2q33–34 IGFBP2 — 6.43 —
3p21.3 rhoA H12 14.92 7.02 7.23
3p21.3 Laminin receptor 18.21 15.00 9.11
3p21.3 Semaphorin — 3.54 —
4q12 PDGF-associated protein 7.49 — —
5q12 CyclinB1 (CCNB1) 3.61 — —
5q31.3 Early growth response protein (EGR1) 8.21 7.48 —
5q31 Interleukin-13 precursor 3.70 3.49 —
5q31 Alpha 1 catenin 3.69 — —
6p21.2 CDKN1,WAF1 6.62 6.45 9.06
8p12 T-plasminogen activator 5.98 4.11 —
9p12 Bcl-2 binding athanogene-1 (BAG-1) 3.95 — —
9q22 Ninjurin-1 8.20 5.58 5.45
9q34.3 NOTCH1 3.82 — 11.22
10q24 Cytohesin-1 4.26 4.02 2.63
11p13 CD59 5.24 — —
11p15.4–15.5 rhoG 3.57 — 3.42
11q13 Fau 12.61 — 16.58
12p13 CD9 11.94 5.48 —
12p13 CD27BP /SIVA 13.97 4.93 8.81
12q13 Cytokeratin 8 17.17 15.00 9.10
12q13 Cytokeratin 18 18.21 15.00 9.10
12q14 CDK4 6.32 3.00 3.75
14q24.3 c-fos 3.35 3.46 —
16p11.2 MAP kinase 1 3.95 — 2.28
16p13.3 Netrin-2 — 6.97 —
16p13.3 Nm23-H4 3.70 5.53 8.03
17q21–22 Cytokeratin 10 11.06 3.42 4.46
17q21–22 Cytokeratin 19 18.17 13.85 9.11
17q21 Desmoplakin III 6.57 6.39 13.33
17q21.3 NDP kinase A (NM23-H1) 4.69 4.93 3.05
17q21.3 NDP kinase B (NM23-H2) 18.21 15.00 11.59
17q21.32 Integrin beta 3 — 3.79 —
17q24–25 EGFRBP-GRB2 3.49 — —
17q25.3 Rho GDP dissociation inhibitor 1 8.53 5.99 10.10
19p13.2 UV excision repair protein RAD23A 5.65 — 14.71
19p13.3 CDC34 — 3.06 4.78
19q13 Apoptosis regulator bax 4.29 4.15 5.14
19 Macrophage migration inhibitory factor (MIF) 12.31 3.93 11.62
20p13 CDC25B 4.29 — 2.56
21q22.1 Cytosolic superoxide dismutase (SOD1) 13.73 3.21 7.53
22q11 DVL1 3.90 — —
Xp11.23 PCTK1 — — 2.84
Xp11.23–3 EPA/TIMP-1 — 6.95 4.26
Xq25 Hepatoma-derived growth factor (HDGF) 10.00 6.93 19.53
CD147 antigen 7.13 14.41 13.39
Zyxin-related protein ZRP-1 10.12 — 8.08
Cytokeratin 7 5.30 5.60 5.38
Cytokeratin 16 5.24 4.47 —
rhoHP1 5.84 7.10 —
P21-rac1, ras-like protein TC25 5.85 — —
PLK1 4.80 — —
PDCD2 4.14 — —
CASP2 3.22 — —
FAST kinase 3.94 — 3.66
CDK5 4.02 — 2.50
c-myc-binding protein MM-1 13.06 6.85 4.56
Cytokeratin 5 — — 2.80
PIG12 — — 4.12
Integrin-beta 8 precursor — — 2.30
IGFBP5 — — 3.49
aRatio of signal intensity to background. MCF7 sources: (a) University of Nottingham, (b) Institute of Cancer Research (Sutton), and (d) McGill University (Montreal).
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subcultures
The majority of genes expressed at high levels in MCF7 cultures
were either intermediate filament markers (1) or genes involved in
their anchorage (2); for example:
(1) Cytokeratin 8, cytokeratin 18 and WAF-1, which have
previously been shown to be differentially expressed in
MCF7 cells (in contrast to MDA-MB 231) (Kuang et al, 1998).
(2) All three cultures had low levels of expression of rhoC and
rhoG, and all but one had higher levels of expression of rhoA
and rhoB. Absolute levels of expression varied widely between
the three different cultures.
The other notable observation involved the two heterodimeric
subunits (H1 and H2) of the metastasis inhibition factor NM23.
NM23-H2 was consistently expressed at high levels, and NM23H1
was consistently expressed at low levels in all subcultures. Low
levels of NM23 correlate with high metastatic potential (Steeg et al,
1988); they are believed to complex with G-proteins and affect
developmental pathways.
DISCUSSION
The viability of using long-term cell lines as models of human
tumours has been questioned in a number of reviews (Corbett et al,
1987; Orth et al, 1994; Sen et al, 1995). It is well known that cells
are subject to selection both during initial culture and subsequent
long-term propagation. Phenotypic diversity has been demon-
strated between established cell lines and the primary tumour from
which they were cultured (Band et al, 1990; Lukashov and
Goudsmit, 1995; Sen et al, 1995). Differences in biological
properties (morphology, phenotype, karyotype, growth rate,
cloning efficiency and tumorigenicity) have been demonstrated
between sublines of haematopoietic cells (Band et al, 1990;
Lukashov and Goudsmit, 1995) and for the breast cell lines
MDA-MB 231 (Crepin et al, 1990) and MCF7 (Osborne et al, 1987).
Murine tumours derived from long-term cell culture passage are
frequently less invasive, far less metastatic and less aggressive than
the same tumour maintained by animal passage only (Corbett et al,
1987). The drug sensitivities for long-term passaged tumours in
vitro can, and do, change frequently (Corbett et al, 1995; Valeriote
et al, 1996). In contrast, the sensitivity pattern for a tumour
passaged in vivo to a given set of agents remains relatively stable
for many years and dozens of transplant generations. Micro-
satellite instability has been demonstrated in ovarian cell lines
(Orth et al, 1994) and is further increased in resistant sublines
(Anthoney et al, 1996). Recently, mutations in hMSH2-deficient
tumour cell lines have been shown to accumulate in a time-
dependent manner in the absence of growth (Richards et al, 1997).
This situation is perhaps more representative of the microenvir-
onment of a tumour than the rapid growth that occurs in cell
culture.
Our CGH results for the four MCF7 subcultures show moderate
variations in two subcultures of the same parental line within the
same laboratory but striking differences between subcultures from
three different laboratories. Whereas Jones et al (2000) have
already demonstrated extensive variation among different MCF7
cell stocks, this is the first report that:
(a) compares and contrasts MCF7 lines from different labora-
tories;
(b) examines the same subculture taken at different time intervals;
and
(c) most importantly, compares the CGH analytical work with
expression array results.
Moreover, our cDNA array results showed that the majority of
expressed genes were related to intermediate filament markers and
cell–cell interaction. Both CGH and expression results demon-
strated a surprising level of divergence between subcultures from
the different laboratories. Comparison between genomic copy
number (as identified by CGH) and gene expression (as measured
by arrays) is complicated by the fact that CGH does not resolve the
fine structure of genome copy number changes. Thus, some lack of
correlation may occur because narrow amplicons are missed in
CGH or narrow deletions are missed, if part of a larger amplified
region (Figure 3).
Since all three subcultures were grown in the same media at the
same time, harvested in exponential phase and RNA extracted
simultaneously, the differences that we observed in gene expres-
sion reflect real differences between the subcultures. Substantial
variations were observed at both the genomic and RNA expression
levels. Each subculture may have been subjected to different
selection pressures or have reacted differently to the same selection
pressures. Furthermore, overexpression can and does occur in the
absence of DNA amplification and vice versa.
The combination of CGH and expression arrays may be useful in
differentiating between genes that are transitorily expressed at
high levels and those for which there is a long-term requirement
for high-level expression. We agree with Pollack et al (1999) that
genes which are both amplified and highly expressed may be more
likely candidates for control of tumour initiation or progression.
These results not only question the utility of long-term culture
cell lines as a basis for genomic analysis and the identification of
signalling pathways, but also provide supportive data for evidence
that cell lines do evolve in culture, thereby weakening the direct
relevance of such cultures as models of human cancer. This work
also reinforces the concern that comparisons of published analyses
of cultures of the same name may be dangerous.
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